Your session is about to expire
← Back to Search
Long-Term Safety Study for Cushing's Syndrome (ISS-CA-2023 Trial)
ISS-CA-2023 Trial Summary
This trial assesses long-term safety of a drug to continue helping 7 Canadian patients.
ISS-CA-2023 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ISS-CA-2023 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Might I be eligible to join the experimental protocol?
"Patients who wish to qualify for this medical trial should have a diagnosis of cushing syndrome and an age between 18-75. A total of 7 individuals are planned to be enrolled in the study."
Does this research study accept individuals of more advanced age?
"This trial is open to individuals aged 18-75. 387 studies are available for those younger than 18, and 1067 research opportunities exist for patients over the age of 65."
Is Participant Group/Arm deemed a secure option for people?
"The safety of Participant Group/Arm was rated as a 3, given its status as an approved Phase 4 trial."
Is this study presently recruiting participants?
"According to clinicaltrials.gov, this particular medical trial does not currently need any more participants. The study was first posted on October 24th 2023 and last updated November 9th 2023; however there are over 1500 other trials actively seeking enrolment at the present moment."
Share this study with friends
Copy Link
Messenger